Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions

Area of Science:

• Immunology
• Otolaryngology
• Pharmacology

Background:

• Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2 inflammatory condition often resistant to conventional therapies.
• Biologic agents targeting key type 2 cytokines (IL-4, IL-5, IL-13) and IgE represent a significant advancement in managing severe or recurrent CRSwNP.

Purpose of the Study:

• To review current evidence on biologic therapies for CRSwNP.
• To discuss challenges, future directions, and precision medicine opportunities in biologic treatment for CRSwNP.

Main Methods:

• Review of current literature on biologic therapies for CRSwNP.
• Analysis of FDA-approved biologics (dupilumab, omalizumab, mepolizumab) and emerging treatments.
• Discussion of clinical trial outcomes, guideline recommendations, and remaining challenges.

Main Results:

• Biologics effectively reduce polyp size, improve symptoms, and enhance quality of life in CRSwNP patients with type 2 inflammation.
• Current guidelines support biologics for select patients with inadequate response to standard care.
• Challenges include high costs, treatment duration uncertainty, lack of comparative data, and biomarker needs.

Conclusions:

• Biologics have transformed CRSwNP management, but personalized selection and integration with surgery are key.
• Further research is needed for non-type 2 inflammation and to address current treatment limitations.
• Precision medicine approaches utilizing biomarkers will optimize outcomes for CRSwNP patients.